$19.00
Manufacturer: Ukraine
Prevention and treatment of parenchymal bleeding, hemorrhage from the mucous membranes, menorrhagia, bleeding from erosions and ulcers of the stomach and intestines. Prevention of bleeding during operations on the liver, lungs, pancreas. Various types of hyperfibrinolysis, including those associated with the use of thrombolytic drugs and massive transfusion of canned blood. As a symptomatic remedy – bleeding due to thrombocytopenia and qualitative inferiority of platelets (dysfunctional thrombocytopenia).
Treatment and prevention of influenza and SARS in children and adults.
Description
Ingredients
active ingredient: 1 package contains aminocaproic acid 1 g.
Dosage form
Powder for oral use.
Basic physical and chemical properties: white or almost white powder, odorless.
Pharmacotherapeutic group
Antihemorrhagic agents. fibrinolysis inhibitors. ATX code B02A A01.
Pharmacodynamics
A specific hemostatic agent used for bleeding caused by increased fibrinolysis.
The mechanism of specific action is due to competitive inhibition of plasminogen activators and partial inhibition of plasmin activity (in high doses), as well as inhibition of biogenic polypeptides – kinins.
It inhibits the activating effect of streptokinase, urokinase and tissue kinases on the processes of fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, and reduces capillary permeability.
Aminocaproic acid has an antiallergic, antiviral effect, enhances the detoxification function of the liver. It inhibits the proteolytic activity associated with the influenza virus. Aminocaproic acid has an inhibitory effect on various stages of the interaction of the virus with sensitive cells, and also inhibits the proteolytic processing of hemagglutinin. As a result, a functionally active protein of the influenza virus is created, which ensures its infectious activity, and the amount of the daughter infectious virus is reduced.
Aminocaproic acid not only exhibits antiviral activity, but also improves some cellular and humoral indicators of the body’s specific defense against respiratory viral infections.
Indications
Prevention and treatment of parenchymal bleeding, hemorrhage from the mucous membranes, menorrhagia, bleeding from erosions and ulcers of the stomach and intestines. Prevention of bleeding during operations on the liver, lungs, pancreas. Various types of hyperfibrinolysis, including those associated with the use of thrombolytic drugs and massive transfusion of canned blood. As a symptomatic remedy – bleeding due to thrombocytopenia and qualitative inferiority of platelets (dysfunctional thrombocytopenia).
Treatment and prevention of influenza and SARS in children and adults.
Contraindications
Hypersensitivity to aminocaproic acid, a tendency to thrombosis and embolism, disseminated intravascular coagulation syndrome, gross hematuria, kidney disease with impaired function, renal failure, hematuria, severe coronary heart disease, cerebrovascular accident.
Directions
Assign orally during or after meals, dissolving the powder in sweet water or drinking it. Divide the daily dose for adults into 3-6 doses, for children – for 3-5 doses.
Moderately pronounced increase in fibrinolytic activity. Adults usually prescribe a daily dose of 5-24 g (5-24 packets).
For children under 1 year of age, a single dose is 0.05 g / kg of body weight (but not more than 1 g). Daily dose for children: under the age of 1 year is 3 g (3 packs), 2-6 years old – 3-6 g (3-6 packs), 7-10 years old – 6-9 g (6-9 packs). For adolescents, the maximum daily dose is 10-15 g (10-15 packets).
Acute bleeding (including gastrointestinal). Adults administer 5 g (5 packets), then 1 g (1 packet) every hour (for no more than 8 hours) until bleeding stops completely. Daily dose for children with acute blood loss: under the age of 1 year – 6 g (6 packets), 2-4 years old – 6-9 g (6-9 packets), 5-8 years old – 9-12 g (9-12 packages), 9-10 years old – 18 g (18 packages).
Subarachnoid hemorrhage. Adults should be prescribed in a daily dose of 6-9 g (6-9 packets).
Traumatic hyphema. Assign at a dose of 0.1 g/kg of body weight every 4 hours (but not more than 24 g/day) for 5 days.
Metrorrhagia associated with intrauterine contraception. Administer 3 g (3 packets) every 6 hours.
Prevention and control of bleeding during dental interventions. Adults appoint 2-3 g (2-3 packets) 3-5 times a day.
For adults, the average daily dose is 10-18 g (10-18 packets), the maximum daily dose is 24 g (24 packets). The course of treatment is 3-14 days.
Influenza, acute respiratory viral infections in children and adults.
The drug is used orally and topically. For oral administration, pre-dissolve the drug at the rate of 1 g (1 package) of aminocaproic acid in two tablespoons of sweetened boiled water, thus obtaining a 5% solution.
Orally, the drug is prescribed in doses:
- children of the first two years of life – 1-2 g (1-2 packets) per day (20-40 ml of a 5% solution) – 1-2 teaspoons 4 times a day (0.02-0.04 g / kg – single dose), can be added to food or drinks;
- children aged 2-6 years – 2-4 g (2-4 packets) per day (40-80 ml of 5% solution) – 1-2 tablespoons 4 times a day;
- children aged 7-10 years – 4-5 g (4-5 packets) per day with water or taken with food or drinks;
- adolescents and adults – 5-8 g (5-8 packets) per day – 1-2 packets 4-5 times a day with water or taken with food or drinks.
For more accurate preparation of the solution and its dosage, it is advisable to use a medical syringe without a needle with a volume of 10 or 20 ml.
At the same time, the use of aminocaproic acid topically is recommended. Every 3 hours, put in each nasal passage for 5-10 minutes cotton turundas, abundantly moistened with a 5% solution of aminocaproic acid prepared in unsweetened water, or instillate (drip) 3-5 drops of this solution into each nasal passage at the indicated time. The solution can be used for inhalation.
In severe hypertoxic forms of influenza or SARS, the doses of the drug can be increased to the maximum level recommended for children with a moderate increase in fibrinolytic activity.
In the treatment of influenza and SARS in adults, aminocaproic acid can be used in the same doses as in adolescents. Aminocaproic acid, if necessary, can be used in combination with other antiviral drugs and interferon and its inducers.
Intranasal instillations of aminocaproic acid solution (3-4 times a day) should be carried out during the epidemic period for the purpose of prevention, which can be supplemented by oral (as in treatment) use of the drug in the foci of infection upon contact with the patient.
The duration of oral administration of aminocaproic acid for influenza and SARS is 3-7 days.
The duration of treatment depends on the severity of the disease and is determined by the doctor individually. Also, the doctor can adjust the dose and prescribe a second course of treatment.
Recent Reviews